ADA: Lilly Bests Novo Again, Takes GLP-1 Pill Foundayo to FDA for Diabetes Approval

Why It Matters

The data positions Foundayo as a potent oral alternative in the crowded GLP‑1 market, potentially reshaping treatment algorithms for type 2 diabetes and challenging Novo’s dominance. Successful FDA approval could generate significant revenue and broaden therapeutic options for patients seeking non‑injectable therapy.

Key Takeaways

• Foundayo cut HbA1c 1.9% vs semaglutide 1.1% at 52 weeks
• 17.2 mg dose achieved 2.2% HbA1c reduction, beating 14 mg semaglutide's 1.4%
• Weight loss 73.6% greater than oral semaglutide in ACHIEVE‑3
• ACHIEVE‑2 showed 1.7% HbA1c drop vs Farxiga's 0.8% at 40 weeks
• Lilly plans FDA T2D filing Q2 2026, targeting oral market share

Pulse Analysis

The oral GLP‑1 class has become a focal point for diabetes innovators, offering patients a needle‑free alternative to injectable therapies. Lilly’s Foundago, already approved for chronic weight management, now leverages robust Phase 3 data to argue for a dual indication in type 2 diabetes. By delivering HbA1c reductions that exceed those of Novo’s oral semaglutide and Farxiga, the drug promises clinicians a more effective add‑on to metformin or insulin, while preserving the convenience of once‑daily dosing.

In the ACHIEVE program, Foundago consistently outperformed its comparators across multiple endpoints. The 9 mg dose achieved a 1.9% HbA1c decline, and the 17.2 mg formulation pushed the reduction to 2.2%, both markedly higher than semaglutide’s results. Weight‑loss outcomes were equally compelling, with a 73.6% greater reduction versus oral semaglutide. These findings, replicated in trials using Farxiga and placebo‑plus‑insulin controls, underscore the drug’s versatility across treatment regimens and suggest a durable efficacy profile that could shift prescribing habits toward oral GLP‑1 options.

Market dynamics intensify as Novo Nordisk seeks to defend its early lead with oral Wegovy, yet Lilly’s data positions Foundago as a credible challenger. A Q2 2026 FDA filing for the diabetes indication could unlock a sizable revenue stream, given the $30‑plus billion global GLP‑1 market. Success would not only diversify Lilly’s portfolio but also expand patient access to non‑injectable therapy, potentially accelerating the overall adoption of oral GLP‑1 agents in diabetes care.